ODM-208 for Prostate Cancer
(CYPIDES Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, ongoing androgen deprivation therapy is required, so you should continue with that treatment.
What data supports the effectiveness of the drug ODM-208 for prostate cancer?
Research Team
Karim Fizazi
Principal Investigator
Gustave Roussy, Cancer Campus, Grand Paris
Eligibility Criteria
This trial is for men over 18 with advanced prostate cancer that's resistant to hormone therapy and has spread. They should have tried at least one hormonal treatment like abiraterone or enzalutamide, and possibly chemotherapy. Good physical condition (ECOG 0-1) is required, along with normal organ function. Men must be on hormone-lowering treatments or had surgery to remove testicles.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ODM-208 to evaluate safety and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ODM-208
Find a Clinic Near You
Who Is Running the Clinical Trial?
Orion Corporation, Orion Pharma
Lead Sponsor
Liisa Hurme
Orion Corporation, Orion Pharma
Chief Executive Officer since 2022
PhD in Biochemistry, University of Helsinki
Hilpi Rautelin
Orion Corporation, Orion Pharma
Chief Medical Officer since 2023
MD, University of Turku